Superworth

Novavax price to book ratio NVAX

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
36.3×
Oct 2025
10-year median
35.6×
10-year range
9.4× to 174×
Peer median
5.6×

Novavax's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Oct 2025, at 36.3×.

On the days it had one over the last ten years, its median was 35.6×, from 9.4× in May 2021 to 174× in Feb 2021.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
202536.3×32.2×41.4×
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
202272.1×13.4×91.0×
202123.4×9.4×174×
202066.7×26.8×77.4×
2019n/m a value too high to mean anything
2018n/m a value too high to mean anything
2017150×145×165×
2016137×63.5×195×
2015123×93.9×200×
2014108×69.6×123×
201398.8×58.5×150×
201287.7×52.2×99.4×
201153.1×51.6×71.2×

Against its peers

Companies in Biotechnology nearest Novavax's size, closest first, today.

CompanyPrice to book ratio
NVAXNovavaxn/m
VCELVericel5.9×
ADMAAdma Biologics5.9×
MGTXMeiraGTx4.1×
KRYSKrystal Biotech6.8×
RGENRepligen4.7×
TECHBIO-TECHNE5.4×
PLXProtalix BioTherapeutics2.9×
HALOHalozyme Therapeutics99.3×
NBIXNeurocrine Biosciences3.9×
EXELExelixis8.7×
Peer median5.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Novavax

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.